The role of apelin in the assessment of response to chemotherapyand prognosis in stage 4 nonsmall cell lung cancer

Ermin, Sinem; Çok, Gürsel; Veral, Alı; Köse, Timur

doi:10.3906/sag-1411-9

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the group of advanced NSCLC patients a significant correlation between apelin-12 level and overall survival was detected. However, there was no association with differential treatment response rates, different chemotherapy regiments or hematological side effects (Ermin et al, 2016 ). Another study revealed, that the expression of APJ protein was higher in lung adenocarcinoma tissue, than in submucous bronchial tissue.…”

Section: Apelin In Cancermentioning

confidence: 99%

The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer

Wysocka

Pietraszek-Gremplewicz

2018

View full text Add to dashboard Cite

Apelin is an endogenous peptide identified as a ligand of the G protein-coupled receptor APJ. Apelin belongs to the family of adipokines, which are bioactive mediators released by adipose tissue. Extensive tissue distribution of apelin and its receptor suggests, that it could be involved in many physiological processes including regulation of blood pressure, body fluid homeostasis, endocrine stress response, cardiac contractility, angiogenesis, and energy metabolism. Additionally, this peptide participates in pathological processes, such as heart failure, obesity, diabetes, and cancer. In this article, we review current knowledge about the role of apelin in organ and tissue pathologies. We also summarize the mechanisms by which apelin and its receptor mediate the regulation of physiological and pathological processes. Moreover, we put forward an indication of apelin as a biomarker predicting cardiac diseases and various types of cancer. A better understanding of the function of apelin and its receptor in pathologies might lead to the development of new medical compounds.

show abstract

Section: Apelin In Cancermentioning

confidence: 99%

The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer

Wysocka

Pietraszek-Gremplewicz

2018

View full text Add to dashboard Cite

show abstract

“…About 85% of the total lung cancer cases were non-small cell lung cancer (NSCLC) which mainly includes squamous cell carcinoma (32) and adenocarcinoma, and these contain approximately 400,000 deaths each year in the world (32-33). Smoking is the main cause (85–90%) of lung cancer (34), and the prevalence of SCC is more than of adenocarcinoma in smokers (33). Metastasis and recurrence are very common in SCC (32) a nd in the invasive types of the tumor with rapid initial growth (35).…”

Section: Discussionmentioning

confidence: 99%

Association of circulating omentin-1 level with lung cancer in smokers

Ansari

Gholamnejad

Meghrazi

et al. 2018

Med. J. Islam. Repub. Iran

View full text Add to dashboard Cite

Background: Omentin has recently been considered as an adipokine secreted from visceral fat and is expressed in the lungs, heart, ovary etc. Various studies have shown that omentin may have an anti-inflammatory role in the inflammatory process and the amount of omentin alters in some cancers, such as colorectal, prostate and renal cells cancers, changes. The serum level of omentin, however, remains unknown in non-patient smokers and the smokers afflicted with lung cancer. Therefore, this study examines the serum levels of omentin in smokers suffering from lung cancer. Methods: The amount of serum omentin was measured in 45 patients with lung cancer and 61 age - and sex - matched controls (30 smokers and 31 non-smokers) using enzyme-linked immunosorbent assay (ELISA) kit. Data were analyzed using SPSS-16, and oneway analysis of variance and Scheffe post hoc test were used to determine and compare the serum levels of omentin in different types of lung malignancies. Significance level was set at p≤0.05. Results: The amount of circulating omentin for healthy non-smokers and non-patient smokers was 3.55±0.57 ng/l and 5.43±1.95 ng/l, respectively (p<0.001). The serum level of omentin was 3.63±0.70 ng/l for smokers afflicted with cancer (p<0.001 compared with nonpatient smokers: 5.43±1.95). Conclusion: The meaningful decrease in omentin levels in smokers with lung cancer can be considered as a risk factor in smokers and can use as a significant factor in the prognosis of lung cancer in these people.

show abstract